In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Nam, Kung-Woo | - |
dc.contributor.author | Jang, Woong Sik | - |
dc.contributor.author | Jyoti, Md. Anirban | - |
dc.contributor.author | Kim, Sukyung | - |
dc.contributor.author | Lee, Byung-Eui | - |
dc.contributor.author | Song, Ho-Yeon | - |
dc.date.accessioned | 2021-08-11T17:44:21Z | - |
dc.date.available | 2021-08-11T17:44:21Z | - |
dc.date.issued | 2016-05-15 | - |
dc.identifier.issn | 0944-7113 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/9115 | - |
dc.description.abstract | Background: The increasing incidence of multidrug-resistant tuberculosis (MDR-TB) infections has created a need for new effective drugs that also target extensively drug-resistant tuberculosis (XDR-TB) and/or augment the activities of existing drugs against tuberculosis. Aim: This study searched natural products for a new lead compound that targets MDR/XDR-TB. Methods: An active compound was purified from the roots of Cynanchum atratum Bunge (Asclepiadaceae) after screening 1640 plant extracts, and its inhibitory effects against MDR/XDR strains and synergistic effects with existing anti-TB drugs were assessed using the resazurin, MGIT, and checkboard assays. Results: (-)-Deoxypergularinine, purified from the roots of C. atratum, inhibited not only M. tuberculosis but also MDR/XDR strains. The minimum inhibitory concentrations (MICs) of (-)-deoxypergularinine for H37Ra, H37Rv, MDR, and XDR strains were all about 12.5 mu g/ml. Moreover, combinations of (-)-deoxypergularinine with the first-line standard drugs rifampicin or isoniazid afforded six-and eight-fold reductions in drug MIC values, respectively, against strain H37Ra. Conclusions: (-)-Deoxypergularinine exerts anti-tubercular activities not only against normal tuberculosis strains but also MDR/XDR strains, and synergic effects with rifampicin and isoniazid for the H37Ra strain. The alkaloid may be valuable for targeting M/XDR M. tuberculosis. (C) 2016 Elsevier GmbH. All rights reserved. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis | - |
dc.type | Article | - |
dc.publisher.location | 독일 | - |
dc.identifier.doi | 10.1016/j.phymed.2016.02.017 | - |
dc.identifier.scopusid | 2-s2.0-84963788165 | - |
dc.identifier.wosid | 000373824600016 | - |
dc.identifier.bibliographicCitation | Phytomedicine, v.23, no.5, pp 578 - 582 | - |
dc.citation.title | Phytomedicine | - |
dc.citation.volume | 23 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 578 | - |
dc.citation.endPage | 582 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Plant Sciences | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Integrative & Complementary Medicine | - |
dc.relation.journalWebOfScienceCategory | Plant Sciences | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Integrative & Complementary Medicine | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | CYNANCHUM-ATRATUM | - |
dc.subject.keywordPlus | PHENANTHROINDOLIZIDINE ALKALOIDS | - |
dc.subject.keywordPlus | (+/-)-DEOXYPERGULARININE | - |
dc.subject.keywordPlus | (+/-)-ANTOFINE | - |
dc.subject.keywordAuthor | Antituberculosis drug | - |
dc.subject.keywordAuthor | (-)-Deoxypergularinine | - |
dc.subject.keywordAuthor | Synergy | - |
dc.subject.keywordAuthor | Rifampicin | - |
dc.subject.keywordAuthor | Isoniazid | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.